Premium
Hemagglutination inhibition of Cromer blood group antibodies with soluble recombinant decay‐accelerating factor
Author(s) -
Daniels G. L.,
Green C. A.,
Powell R. M.,
Ward T.
Publication year - 1998
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1046/j.1537-2995.1998.38498257370.x
Subject(s) - hemagglutination , antibody , recombinant dna , hemagglutination tests , virology , medicine , immunology , microbiology and biotechnology , biology , genetics , gene
BACKGROUND: Cromer blood group antigens are located on decay‐ accelerating factor (DAF, CD55), which contains four short consensus repeats (SCRs). Cromer system antibodies may be of clinical significance in blood transfusion. STUDY DESIGN AND METHODS: Soluble recombinant DAF (srDAF) constructs, consisting of all four SCRs or of only two SCRs, were expressed in the yeast Pichia pastoris. They are used in hemagglutination‐inhibition tests with Cromer system antibodies and with DAF‐specific monoclonal antibodies. RESULTS: The srDAF inhibited hemagglutination by all Cromer system alloantibodies in undiluted serum. Antibodies to antigens of other blood group systems were not inhibited by the srDAF. Hemagglutination‐inhibition tests with domain‐deleted srDAF showed that UMC is on SCR‐4 and confirmed that Tca, TcaTcb, and WESb are on SCR‐1; Dra is on SCR‐3; and Cra is on SCR‐ 4. CONCLUSIONS: Hemagglutination inhibition with srDAF is useful in the recognition of antibodies that belong to the Cromer blood group system and facilitates pretransfusion testing. This use of domain‐deleted srDAF provides an easy method of determining epitope location on DAF and is an aid to more precise identification of Cromer system antibodies.